体外诊断行业周报：重庆病理服务价格改革落地，病理价格改革步伐有望加快-20260111

Investment Rating - The report maintains an "Accumulate" rating for the in vitro diagnostics industry [7]. Core Views - The in vitro diagnostics (IVD) market is experiencing significant growth, with the domestic biochemical diagnostics sector having largely completed its localization process. The report suggests focusing on the growth potential in immunodiagnostics, particularly in chemiluminescence and molecular diagnostics such as PCR [4][54]. - Recent policy changes in Chongqing regarding pathology service pricing are expected to streamline and clarify pricing structures, which may enhance the role of pathology in precision medicine [4][54]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 7.81% this week, ranking 6th among 31 primary industries. The in vitro diagnostics sector specifically increased by 8.52% [9][18]. - The medical services sub-sector reported a 12.34% increase, while other related sectors also showed positive growth [18][19]. Valuation Metrics - As of the end of the week, the in vitro diagnostics sector had a PE ratio of 41.66X, with a one-year maximum of 41.97X and a minimum of 20.96X. The current PB ratio stands at 1.90X, with a one-year maximum of 2.01X and a minimum of 1.53X [3][28]. - The PE ratio increased by 3.30X and the PB ratio by 0.15X compared to the previous week [28]. Company Performance - Top-performing companies in the medical services sector include Anbiping (+39.5%), Rejing Biological (+27.1%), and Botuo Biological (+19.0%). Conversely, Mingde Biological (-2.2%) and others showed weaker performance [2][23].